| Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B A Koshkaryev, R Thekkedath, C Pagano, I Meerovich, VP Torchilin Journal of drug targeting 19 (8), 606-614, 2011 | 55 | 2011 |
| Lysosome-Targeted Octadecyl-Rhodamine B-Liposomes Enhance Lysosomal Accumulation of Glucocerebrosidase in Gaucher‘S Cells In Vitro R Thekkedath, A Koshkaryev, VP Torchilin Nanomedicine 8 (7), 1055-1065, 2013 | 41 | 2013 |
| Screening and optimization of ligand conjugates for lysosomal targeting I Meerovich, A Koshkaryev, R Thekkedath, VP Torchilin Bioconjugate chemistry 22 (11), 2271-2282, 2011 | 34 | 2011 |
| In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL I Skidan, B Miao, RV Thekkedath, P Dholakia, A Degterev, V Torchilin Drug delivery 16 (1), 45-51, 2009 | 32 | 2009 |
| Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof T Cavanagh, SP Barman, T Hao, TB Leland, RV Thekkedath US Patent 9,822,142, 2017 | 8 | 2017 |
| A HPLC method for the quantitative determination of N-(2-hydroxy-5-nitrophenylcarbamothioyl)-3, 5-dimethylbenzamide in biological samples I Skidan, J Grunwald, R Thekkedath, A Degterev, V Torchilin Journal of Chromatography B 879 (19), 1610-1616, 2011 | 7 | 2011 |
| Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof SP Barman, RV Thekkedath, K Barman, T Cavanagh, T Hao, TB Leland US Patent 9,815,865, 2017 | 5 | 2017 |
| Membrane-adherent self-assembled system for treatment of ocular disorders SP Barman, KL Ward, AM Cromwick, K Barman, RV Thekkedath US Patent 9,901,544, 2018 | 3 | 2018 |
| Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof T Cavanagh, SP Barman, HAO Tian, TB Leland, RV Thekkedath | 3 | 2013 |
| Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof T Cavanagh, SP Barman, T Hao, TB Leland, RV Thekkedath US Patent 10,174,071, 2019 | 2 | 2019 |
| OcuSurf: a nanostructured, membrane-interactive, biphasic ocular drug delivery system for once/day administration of water-insoluble ophthalmic medications R Thekkedath, K Barman, SP Barman Investigative Ophthalmology & Visual Science 55 (13), 458-458, 2014 | 1 | 2014 |
| Development of cell-specific and organelle-specific delivery systems by surface modification of lipid-based pharmaceutical nanocarriers RV Thekkedath Northeastern University, 2012 | 1 | 2012 |
| Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof T Cavanagh, SP Barman, T Hao, TB Leland, RV Thekkedath US Patent 11,814,408, 2023 | | 2023 |
| Membrane-adherent self-assembled systems for treatment of ocular disorders SP Barman, RV Thekkedath, KL Ward, AM Cromwick, K BARMAN | | 2022 |
| Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof T Cavanagh, SP Barman, T Hao, TB Leland, RV Thekkedath US Patent 10,954,263, 2021 | | 2021 |
| Polymorf form af fluticasonpropionat T Hao, RV Thekkedath, T Cavanagh, SP Barman, TB Leland | | 2020 |
| Polymorphic form of fluticasone propionate T CAVANAGH, SP Barman, HAO Tian, TB Leland, RV Thekkedath | | 2020 |
| Membrane-adherent self-assembled systems for treatment of ocular disorders SP Barman, KL Ward, AM Cromwick, K Barman, RV Thekkedath US Patent 10,603,273, 2020 | | 2020 |
| Fluticasone propionate nanocrystals T CAVANAGH, SP Barman, HAO Tian, TB LELAND, RV THEKKEDATH | | 2019 |
| Membrane-adherent self-assembled systems for treatment of ocular disorders RVT Shikha P. Barman WO Patent 2015168523 A1, 2015 | | 2015 |
